Cenix BioScience and CellCentric Sign Framework Research Agreement for RNAi-Based Target Validation.
Cenix BioScience GmbH announced that it has signed a framework research agreement to support CellCentric Ltd through cell-based validation of novel therapeutic drug targets for oncology.
Cenix will apply its expertise in combining high throughput (HT) applications of RNAi-based gene silencing with high content phenotypic analyses in cultured human cells. The initial project will focus on the in vitro validation of several candidate drug targets chosen by CellCentric to offer high therapeutic anti-cancer potential. Multi-parametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be adapted to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes across multiple cell lines. Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.
Other news from the department business & finance
